Tyra Biosciences (TYRA) Announces FDA Orphan Drug Designation for TYRA-300 for the Treatment of Achondroplasia streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
CARLSBAD, Calif., Aug. 1, 2023 /PRNewswire/ Tyra Biosciences, Inc. , a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large.
Tyra Biosciences (TYRA) Expands Development of TYRA-300 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance.
-TYRA-300 is the first oral, FGFR3-selective agent to be evaluated in the clinic-
-Conference call and webcast today, Nov. 29th, at 9:00 am ET-
CARLSBAD, Calif., Nov. 29, 2022 /PRNewswire/ Tyra.